MedTrace Logo

Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer

NCT02494791 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 886

Last updated 2022-05-17

No results posted yet for this study

Summary

This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk. These women will be referred to genetic counselling for testing and those found to have Lynch Syndrome will be asked to invite first degree relatives to participate and undergo genetic testing for Lynch Syndrome. Screening guidelines and risk reducing surgery options for participants found to have Lynch Syndrome will be reinforced by the study and adherence to these guidelines will be assessed annually for ten years following Lynch Syndrome diagnosis to assess the impact and cost-effectiveness of this enhanced screening approach.

Conditions

  • Lynch Syndrome
  • Endometrial Neoplasms
  • Ovarian Neoplasms
  • Colorectal Neoplasms

Interventions

BEHAVIORAL

Questionnaire, Educational Material

Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.

Sponsors & Collaborators

  • Mount Sinai Hospital, Canada

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • Toronto Metropolitan University

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Sarah Ferguson, MD · Princess Margaret Cancer Centre

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2020-07-31
Completion
2025-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02494791 on ClinicalTrials.gov